Last reviewed · How we verify
SL-BUP
At a glance
| Generic name | SL-BUP |
|---|---|
| Also known as | sublingual buprenorphine, Suboxone |
| Sponsor | NYU Langone Health |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study
- Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study
- A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder (PHASE4)
- Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR) (PHASE3)
- Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (PHASE2)
- EXHIT ENTRE Comparative Effectiveness Trial (PHASE2, PHASE3)
- OXD01 in Combination With Sublingual Buprenorphine/Naloxone for Treatment of Opioid Use Disorder (NA)
- Medication Treatment for Opioid Use Disorder in Expectant Mothers (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SL-BUP CI brief — competitive landscape report
- SL-BUP updates RSS · CI watch RSS
- NYU Langone Health portfolio CI